AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 31 min read$CMPS

COMPASS Pathways 2026: Revenue ($10.01M), EPS ($0.31) — 10-Q Summary

COMPASS Pathways reported a net loss of $9.83M for 2026, narrowing from $137.72M in 2025. Revenue was $10.01M, with a diluted loss per share of $0.31. The company's treatments COMP005 and COMP006 met primary endpoints in Phase 3 trials for treatment-resistant depression, with ongoing FDA reviews and planned expansions.

Original reporting
tradingview.com
Published Nov 3, 2026, 1:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
COMPASS Pathways 2026: Revenue ($10.01M), EPS ($0.31) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$CMPSNeutralLow
01

Why it matters

The earnings release provides fresh quantitative data and clinical milestones, offering a basis for short‑term price movement and longer‑term valuation reassessment.

02

Market read

First‑time disclosure of 2026 results and trial outcomes makes this a primary earnings event for CMPS, with limited broader market impact.

03

What to watch

Potential FDA approval timeline and reimbursement landscape could materially affect valuation.

Relevance 7/10Novelty 7/10Timing: post‑market release

Background

COMPASS Pathways plc (CMPS) filed its 2026 10‑Q, showing a narrowed loss and positive phase‑3 results for its TRD program.

Company-level read

Ticker impact

$CMPSNeutralHigh confidence
Context

The 10‑Q reports COMPASS Pathways' 2026 net loss of $9.83 M, revenue of $10.01 M and phase‑3 trial success, constituting the first public disclosure of these results.

Expected impact

likely modest pressure as the market prices in the loss, tempered by upbeat clinical data.

Evidence & confidence

Losses remain sizable, but improvement and trial success could limit sell‑off.

Market effects

Sector

Phase‑3 success may boost sentiment in the biotech/psychiatric‑treatment sector.

Regional

Limited to investors focused on UK‑listed biotech firms.

Global

Minimal; impact confined to niche mental‑health therapeutics space.

Counterpoint

What could challenge this read

Despite the loss, the trial data could spark a rally if investors focus on future upside.

Key entities

  • company
    COMPASS Pathways plc

    Biopharma developing psychedelic‑based therapies for treatment‑resistant depression.

Read at source← All news

Related articles

NOV 3
$CMPSMedAI 8/10

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights

COMPASS Pathways plc (CMPS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights • Final NDA submission nearing completion and will be filed in the next two weeks • Launch readiness on track for expected launch in H12027, subject to FDA approval • Data from two positive Ph

SEC EDGAR 8-K3 min
NOV 3
$CMPSMedAI 8/10

An extra dose extended a depression treatment’s effect to one year in trial data.

Compass Pathways (CMPS) is nearing completion of its NDA submission for COMP360, a treatment for treatment-resistant depression (TRD), with a filing expected in two weeks. Positive Phase 3 trial data shows durability of effect up to one year. The company aims for a H1 2027 launch, subject to FDA approval. COMP360 is seen as a potential blockbuster with a large market opportunity. Compass also has a late-stage PTSD trial ongoing and a strong cash position into 2028.

stocktitan.net2 min
OCT 26
$CMPSMed

B.Riley reiterates Buy on Compass Pathways stock, $22 target

B.Riley reiterated a Buy rating and $22 target on Compass Pathways (CMPS) after the VA selected sites for psychedelic deployment. CMPS is up 78% over the past year and 62% YTD, trading at $11.15. The company's COMP360 therapy could begin dosing soon, with FDA approval possible within 3-6 months. B.Riley estimates significant revenue potential from VA patients. Analysts highlight positive trial data and strong financial position.

investing.com2 min
OCT 24
$CMPSHighAI 9/10

Tovecimig Plus Paclitaxel Improves ORR vs Paclitaxel Alone in Biliary Tract Cancer

Tovecimig (CTX-009) plus paclitaxel showed improved objective response rates (18.0% vs 5.3%) over paclitaxel alone in advanced biliary tract cancer, meeting the primary endpoint of the phase 2/3 COMPANION-002 trial. Median PFS was 4.7 months vs 2.6 months, but OS was similar (8.9 vs 9.4 months). The trial involved 168 patients and was presented at the 2026 ESMO Congress. According to Compass Therapeutics, the combination represents a promising new strategy for biliary tract cancer.

onclive.com3 min
OCT 16
$CMPSMedAI 8/10

Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?

Compass Pathways presented real-world analyses showing that treatment-resistant depression (TRD) has significant economic burden during treatment-resistant episodes, with costs declining as patients stabilize. Their psilocybin formulation, COMP360, showed sustained clinical benefit in phase 3 trials, with 25% and 39% of participants achieving meaningful symptom reduction in COMP005 and COMP006, respectively, maintained through week 26.

psychiatrictimes.com3 min